COLL · CIK 0001267565 · operating
Collegium Pharmaceutical is a specialty pharmaceutical company focused on pain management medications. The company develops and commercializes both opioid and non-opioid treatments for chronic and acute pain conditions, as well as medications addressing opioid-related side effects. Its portfolio includes Belbuca, a buccal film containing buprenorphine for severe persistent pain; Xtampza ER, an abuse-deterrent extended-release oxycodone formulation; Nucynta ER and Nucynta IR, which deliver tapentadol in extended and immediate-release forms; and Symproic, an oral medication for opioid-induced constipation in chronic non-cancer pain patients. The company also markets Jornay PM, a central nervous system stimulant containing methylphenidate for attention deficit hyperactivity disorder treatment.
The company operates with approximately 423 full-time employees and maintains its headquarters in Stoughton, Massachusetts. Collegium was incorporated in Virginia in 2002 and is listed on the Nasdaq exchange. The company's product portfolio generates revenue through specialty pharmaceutical sales, with a market capitalization of $1.3 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.46 | $0.54 | +27.8% | |
| 2024 | $0.36 | $0.39 | -56.1% | |
| 2023 | $0.82 | $0.99 | +490.5% | |
| 2022 | $-0.21 | $-0.21 | +71.2% | |
| 2021 | $-0.73 | $-0.73 | -465.0% | |
| 2020 | $0.20 | $0.20 | -25.9% | |
| 2019 | $0.27 | $0.27 | +0.0% | |
| 2018 | $0.27 | $0.27 | — | |
| 2017 | — | — | — | |
| 2016 | $-0.46 | $-3.88 | +0.0% | |
| 2015 | $-0.46 | $-0.46 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001628280-26-011992 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001558370-25-001801 | SEC ↗ |
| 2023-12-31 | 2024-02-22 | 0001558370-24-001526 | SEC ↗ |
| 2022-12-31 | 2023-02-23 | 0001558370-23-001900 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0001558370-22-001927 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001558370-21-001814 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001558370-20-001625 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001558370-19-001187 | SEC ↗ |
| 2017-12-31 | 2018-03-07 | 0001558370-18-001644 | SEC ↗ |
| 2016-12-31 | 2017-03-10 | 0001558370-17-001629 | SEC ↗ |
| 2015-12-31 | 2016-03-18 | 0001558370-16-004252 | SEC ↗ |